<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474328</url>
  </required_header>
  <id_info>
    <org_study_id>16LO0290</org_study_id>
    <nct_id>NCT03474328</nct_id>
  </id_info>
  <brief_title>AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease</brief_title>
  <official_title>AlcoChange: An Open Label Pilot Study of Smartphone Monitoring for Alcoholic Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Free Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Free Hospital NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alcohol contributes to over 5% of deaths worldwide, and death rates from alcohol-related&#xD;
      liver disease (ARLD) in the UK continue to rise sharply. On-going alcohol use in ARLD leads&#xD;
      to markedly increased mortality (Thursz et al, 2015), and maintaining abstinence is a key&#xD;
      therapeutic goal. However, there are no effective pharmacological therapies for maintaining&#xD;
      abstinence. Brief intervention (BI) is an effective psychological tool for reducing alcohol&#xD;
      use, but is difficult to scale widely.&#xD;
&#xD;
      AlcoChange is a smartphone app and breathalyser (AlcoChange), which facilitates&#xD;
      self-monitoring and delivers BIs in response to patient triggers. The aim of this open-label&#xD;
      study is provide AlcoChange to 60 patients with ARLD, to determine compliance with the&#xD;
      app/breathalyser and changes in self-reported alcohol consumption.&#xD;
&#xD;
      Recruitment of inpatients/outpatients with ARLD and recent alcohol use will take place at&#xD;
      Royal Free London. The inclusion criteria are: intent to maintain abstinence, possession of&#xD;
      compatible smartphone. The exclusion criteria are: inability to provide consent. Participants&#xD;
      will be assessed at baseline and 3-months. The primary endpoint is self-reported alcohol use&#xD;
      (units/week, timeline follow-back). Secondary endpoint is compliance with the app (monitored&#xD;
      remotely).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">April 25, 2016</start_date>
  <completion_date type="Anticipated">November 2018</completion_date>
  <primary_completion_date type="Anticipated">November 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Self-reported alcohol consumption (average/week)</measure>
    <time_frame>3-month study period</time_frame>
    <description>Assessed by time line follow back method over study period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance with the app (no. of logins, duration spent on the app)</measure>
    <time_frame>3-month study period</time_frame>
    <description>This will be assessed independently, and for associations of compliance with the app and changes in alcohol consumption (primary endpoint)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Alcohol-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AlcoChange</intervention_name>
    <description>Smartphone app and breathalyser</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  presence of ARLD&#xD;
&#xD;
          -  age 18-70&#xD;
&#xD;
          -  intent to maintain abstinence&#xD;
&#xD;
          -  possession of compatible smartphone&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - inability to provide consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>March 15, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>August 29, 2018</last_update_submitted>
  <last_update_submitted_qc>August 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Royal Free Hospital NHS Foundation Trust</investigator_affiliation>
    <investigator_full_name>Gautam Mehta</investigator_full_name>
    <investigator_title>Honorary Consultant and Senior Lecturer in Hepatology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Liver Diseases, Alcoholic</mesh_term>
    <mesh_term>Alcohol-Related Disorders</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

